CN112755055B - Application of lactobacillus plantarum NA136 and cannabidiol monomer combination in preparation of product for treating rheumatoid arthritis - Google Patents
Application of lactobacillus plantarum NA136 and cannabidiol monomer combination in preparation of product for treating rheumatoid arthritis Download PDFInfo
- Publication number
- CN112755055B CN112755055B CN202011634182.XA CN202011634182A CN112755055B CN 112755055 B CN112755055 B CN 112755055B CN 202011634182 A CN202011634182 A CN 202011634182A CN 112755055 B CN112755055 B CN 112755055B
- Authority
- CN
- China
- Prior art keywords
- cannabidiol
- monomer
- lactobacillus plantarum
- reducing
- rheumatoid arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title claims abstract description 73
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title claims abstract description 69
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title claims abstract description 69
- 229950011318 cannabidiol Drugs 0.000 title claims abstract description 69
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title claims abstract description 69
- 239000000178 monomer Substances 0.000 title claims abstract description 66
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 56
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 43
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 43
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000002829 reductive effect Effects 0.000 claims abstract description 22
- 210000002966 serum Anatomy 0.000 claims abstract description 21
- 239000002158 endotoxin Substances 0.000 claims abstract description 18
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 17
- 206010003246 arthritis Diseases 0.000 claims abstract description 15
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 14
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 12
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 12
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 9
- 208000024891 symptom Diseases 0.000 claims abstract description 9
- 206010051728 Bone erosion Diseases 0.000 claims abstract description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 8
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 8
- 230000008355 cartilage degradation Effects 0.000 claims abstract description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 244000025254 Cannabis sativa Species 0.000 claims description 8
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 8
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000009120 camo Nutrition 0.000 claims description 8
- 235000005607 chanvre indien Nutrition 0.000 claims description 8
- 239000011487 hemp Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000007605 air drying Methods 0.000 claims description 4
- 229960003453 cannabinol Drugs 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000002953 preparative HPLC Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 28
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 229940076144 interleukin-10 Drugs 0.000 description 9
- 230000008961 swelling Effects 0.000 description 7
- 210000001503 joint Anatomy 0.000 description 6
- 238000008157 ELISA kit Methods 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101001076393 Rattus norvegicus Interleukin-1 beta Proteins 0.000 description 1
- 101001033266 Rattus norvegicus Interleukin-10 Proteins 0.000 description 1
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Group of | TNF-α(pg/mL) | IL-17(pg/mL) | IL-10(pg/mL) |
Control group | 66.77±4.31 ** | 2.13±0.33 ** | 90.26±4.21 ** |
Model set | 223.98±9.16 | 3.70±0.28 | 20.98±5.93 |
NA136 group | 113.98±4.55 ** | 2.65±0.17 ** | 64.31±3.88 ** |
Cannabidiol monomer group | 110.99±8.77 ** | 2.31±0.22 ** | 57.39±4.64 ** |
NA136+ cannabidiol monomer set | 78.10±5.93 ** | 2.23±0.14 ** | 87.73±6.35 ** |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011634182.XA CN112755055B (en) | 2020-12-31 | 2020-12-31 | Application of lactobacillus plantarum NA136 and cannabidiol monomer combination in preparation of product for treating rheumatoid arthritis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011634182.XA CN112755055B (en) | 2020-12-31 | 2020-12-31 | Application of lactobacillus plantarum NA136 and cannabidiol monomer combination in preparation of product for treating rheumatoid arthritis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112755055A CN112755055A (en) | 2021-05-07 |
CN112755055B true CN112755055B (en) | 2022-12-13 |
Family
ID=75697897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011634182.XA Active CN112755055B (en) | 2020-12-31 | 2020-12-31 | Application of lactobacillus plantarum NA136 and cannabidiol monomer combination in preparation of product for treating rheumatoid arthritis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112755055B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024160742A1 (en) * | 2023-01-30 | 2024-08-08 | Mrm Health N.V. | Microbial compositions for treating joint inflammation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2414933B (en) * | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
CN110575448A (en) * | 2018-06-08 | 2019-12-17 | 云南汉素生物科技有限公司 | Cannabidiol composition and application thereof |
CN108641988B (en) * | 2018-06-15 | 2021-09-21 | 吉林省农业科学院 | Lactobacillus plantarum NA136 and application thereof in relieving non-alcoholic fatty liver disease |
CN111019857B (en) * | 2019-12-16 | 2021-03-19 | 吉林省命之元生物科技有限公司 | Lactobacillus plantarum HG20 strain and application thereof |
CN111807932A (en) * | 2020-03-20 | 2020-10-23 | 浙江双子智能装备有限公司 | Method for extracting and purifying cannabidiol from cannabis sativa |
-
2020
- 2020-12-31 CN CN202011634182.XA patent/CN112755055B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN112755055A (en) | 2021-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
CN111019857B (en) | Lactobacillus plantarum HG20 strain and application thereof | |
CN114717147A (en) | Metazoan prepared from Lactobacillus rhamnosus and used for relieving fatty liver and obesity, and application thereof | |
CN113493491B (en) | Polypeptide for preventing or treating ulcerative colitis | |
CN112755055B (en) | Application of lactobacillus plantarum NA136 and cannabidiol monomer combination in preparation of product for treating rheumatoid arthritis | |
CN113480676A (en) | Oligogalacturonic acid polysaccharide, compound, preparation method and application thereof | |
CN107802642B (en) | Pharmaceutical composition containing hydrotalcite and pharmaceutical application | |
CN117645955A (en) | Eubacterium rectum with function of promoting recovery of intestinal epithelial cells and application thereof | |
CN116574659A (en) | Bifidobacterium longum subspecies infantis capable of relieving rheumatoid arthritis and application thereof | |
CN111743910A (en) | Application of baicalin in preparation of medicine for improving diabetic lung injury | |
CN108570116B (en) | Pleurotus citrinopileatus polysaccharide, preparation method and medical application in preventing and treating diabetes | |
CN114796283B (en) | Application of five-cereal worm extract in preparation of medicine for treating digestive diseases and pharmaceutical composition | |
CN114917208A (en) | Application of white spirit in preparing medicine for improving intestinal barrier function and intestinal flora | |
CN114369146A (en) | Achroman bacterium Amuc _2172 protein and preparation method and application thereof | |
CN111560335A (en) | Bifidobacterium lactis for relieving asthma and application thereof | |
CN115252638B (en) | Preparation method and application of quinoa dietary fiber for improving intestinal inflammation | |
CN105497167A (en) | New application of radix ranunculi ternati in preparation of medicine for treating and/or preventing ulcerative colitis | |
CN117987329B (en) | Lactobacillus reuteri Glory LR15 composition capable of relieving anaphylactic reaction and application thereof | |
CN118267401B (en) | Tremella pedicel head polysaccharide faeces fungus and application thereof in colonitis | |
CN113577076B (en) | Application of gelsemine in preparation of medicine for treating acute lung injury | |
CN117815261B (en) | New medical application of saw palmetto fruit extract and soft capsule thereof | |
CN114292343B (en) | Preparation method of perennial cerasus extracellular polysaccharide and intracellular polysaccharide and application of perennial cerasus extracellular polysaccharide and intracellular polysaccharide in regulating intestinal microbial flora and reducing blood sugar | |
CN114712351A (en) | Application of rhynchophylline in preparation of medicine for treating inflammatory enteritis | |
CN118717792A (en) | Application of Antrodia camphorata polysaccharide in preparation of antidepressant drugs or health products | |
CN118267401A (en) | Tremella pedicel head polysaccharide faeces fungus and application thereof in colonitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 130000 no.1363 ecological street, Jingyue high tech Development Zone, Changchun, Jilin Province Patentee after: Jilin Academy of Agricultural Sciences (China Agricultural Science and Technology Northeast Innovation Center) Country or region after: China Address before: 130033 Jilin province Changchun City Jingyue Development Zone Caiyu Street No. 1363 Patentee before: Jilin Academy of Agricultural Sciences Country or region before: China |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240507 Address after: Warehouse 3 for the annual production of 300000 sets of automotive door panel systems and automotive pipe fittings connection systems at No. 8755 Xihu Road, Changchun Automotive Economic and Technological Development Zone, Jilin Province, 130000 Patentee after: Jilin Huayu Kangyuan Biotechnology Co.,Ltd. Country or region after: China Address before: 130000 no.1363 ecological street, Jingyue high tech Development Zone, Changchun, Jilin Province Patentee before: Jilin Academy of Agricultural Sciences (China Agricultural Science and Technology Northeast Innovation Center) Country or region before: China |
|
TR01 | Transfer of patent right |